Skip to main content

MARSHALL WACE, LLP

Position in NVAX — Novavax Inc

CIK 1318757 LONDON, X0

Position in NVAX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$6,149,121
-$3,343,721 QoQ
Shares Held
652,773
-44.0% QoQ
Ownership
0.396%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#26
of 263 holders
Holding Since
Dec 2020
13 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in NVAX Over Time

Shares Held

Position Value (USD)

Derivatives in NVAX

reported options exposure · as of Jun 30, 2026
CallValue
$0
CallShares
0
PutValue
$942
PutShares
100

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,014,740,742 across 267 Biotechnology names. NVAX ranks #85 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in NVAX

Export CSV
18 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $942 100
2026-06-30 $6,149,121 652,773
2026-03-31 $814 100
2026-03-31 $9,492,842 1,166,197
2026-03-31 $814 100
2025-12-31 $6,246,985 929,611
2025-12-31 $2,688 400
2025-09-30 $8,670 1,000
2025-09-30 $438,658 50,595
2024-09-30 $1,880,821 148,917
2024-06-30 $4,591,655 362,690
2022-06-30 $8,236,874 160,157
2022-03-31 $1,219,202 16,554
2021-12-31 $6,522,704 45,591
2021-09-30 $3,287,936 15,860
2021-06-30 $8,684,540 40,905
2021-03-31 $9,202,932 50,758
2020-12-31 $320,814 2,877